Shots:
- BMS has entered into a definitive agreement to acquire Orbital, strengthening & diversifying its cell therapy portfolio
- As per the deal, BMS will acquire Orbital, incl. its asset, OTX-201 & RNA platform, in an all-cash transaction of $1.5B
- OTX-201 is a preclinical circular RNA therapy encoding a CD19 CAR for in vivo expression delivered via targeted LNPs, whereas Orbital’s AI-driven RNA platform integrates circular & linear RNA engineering for advanced LNP delivery
Ref: BMS| Image: Orbital Therapeutics | Press Release
Related News:- Novo Nordisk to Acquire Akero Therapeutics for ~$5.2B, Expanding its MASH Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
